Filing Details

Accession Number:
0001209191-21-027939
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-22 16:04:14
Reporting Period:
2021-04-21
Accepted Time:
2021-04-22 16:04:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1708493 Harpoon Therapeutics Inc. HARP () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1134655 Ansbert Gadicke C/O Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1687078 Mpm Oncology Impact Management Lp C/O Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1691428 L.p. Fund Impact Oncology Ubs C/O Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1721035 Mpm Oncology Impact Management Gp Llc C/O Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1721036 L.p. Management (Cayman) Fund Impact Oncology C/O Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-04-21 8,417 $18.94 7,020,675 No 4 S Indirect See Footnote
Common Stock Disposition 2021-04-21 555 $19.48 7,020,120 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Footnotes
  1. Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021.
  2. The shares were sold as follows: 7,398 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,019 by MPM Asset Management LLC ("AM LLC").
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.40 to $19.33 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 309,264 by AM LLC and 3,805,468 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
  5. The shares were sold as follows: 488 by UBS Oncology and 67 by AM LLC.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.40 to $19.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  7. The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 309,197 by AM LLC and 3,804,980 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.